Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,211,520
  • Shares Outstanding, K 1,770,647
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • 60-Month Beta 0.58
  • Price/Sales 5.47
  • Price/Cash Flow 10.72
  • Price/Book 29.35
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 19.66% ( -5.72%)
  • Historical Volatility 23.72%
  • IV Percentile 57%
  • IV Rank 29.49%
  • IV High 29.42% on 04/12/24
  • IV Low 15.58% on 09/01/23
  • Put/Call Vol Ratio 0.73
  • Today's Volume 7,088
  • Volume Avg (30-Day) 24,323
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 383,590
  • Open Int (30-Day) 344,686

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.35
  • Number of Estimates 6
  • High Estimate 2.50
  • Low Estimate 2.29
  • Prior Year 2.46
  • Growth Rate Est. (year over year) -4.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
160.00 +1.47%
on 04/12/24
182.30 -10.95%
on 03/28/24
-16.85 (-9.40%)
since 03/26/24
3-Month
160.00 +1.47%
on 04/12/24
182.89 -11.23%
on 03/12/24
-2.05 (-1.25%)
since 01/26/24
52-Week
130.96 +23.97%
on 06/28/23
182.89 -11.23%
on 03/12/24
+0.54 (+0.34%)
since 04/26/23

Most Recent Stories

More News
AbbVie: Q1 Earnings Snapshot

AbbVie: Q1 Earnings Snapshot

ABBV : 162.99 (-2.57%)
Stock Index Futures Climb on Upbeat Big Tech Earnings, U.S. Inflation Data Looms

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment,...

ESM24 : 5,132.00 (+0.98%)
NQM24 : 17,798.00 (+1.31%)
GOOGL : 170.25 (+9.13%)
MSFT : 409.92 (+2.73%)
META : 439.19 (-0.50%)
TXT : 86.42 (+1.79%)
IBM : 166.20 (-1.60%)
NEM : 42.81 (-1.38%)
XOM : 117.00 (-3.57%)
ABBV : 162.99 (-2.57%)
CVX : 163.61 (-1.01%)
CL : 89.36 (+0.08%)
Buying the Dip in These 3 Undervalued Dividend Stocks

All three of these stocks look intriguing.

MCD : 274.37 (-0.45%)
COP : 129.90 (-0.16%)
ABBV : 162.99 (-2.57%)
Stocks Set to Open Higher as Investors Await Key U.S. Inflation Data and Big Tech Earnings

June S&P 500 E-Mini futures (ESM24) are up +0.48%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.58% this morning as market participants looked ahead to earnings reports from some of the biggest...

ESM24 : 5,132.00 (+0.98%)
NQM24 : 17,798.00 (+1.31%)
NFLX : 556.41 (-1.49%)
AMD : 158.07 (+2.80%)
MU : 114.15 (+2.30%)
ULTA : 410.34 (+0.57%)
PARA : 12.00 (-1.48%)
AXP : 236.68 (-0.18%)
TSLA : 169.26 (-0.54%)
META : 439.19 (-0.50%)
MSFT : 409.92 (+2.73%)
GOOGL : 170.25 (+9.13%)
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income

The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.

JPM : 194.55 (+0.61%)
XOM : 117.00 (-3.57%)
PGR : 206.71 (-1.60%)
ABBV : 162.99 (-2.57%)
TT : 302.49 (+1.04%)
META : 439.19 (-0.50%)
MSFT : 409.92 (+2.73%)
AMZN : 177.23 (+2.05%)
JEPI : 56.36 (+0.45%)
New Home Sales Due Next Week in Canada

Monday U.S. Featured Earnings Verizon Communications Inc. (NYSE:VZ) (Q1) EPS of $1.12, ...

PSK.TO : 26.84 (-0.04%)
CDNS : 285.21 (+2.93%)
TFC : 38.53 (+1.47%)
TSLA : 169.26 (-0.54%)
V : 276.45 (+0.47%)
META : 439.19 (-0.50%)
TMO : 572.27 (+0.09%)
IBM : 166.20 (-1.60%)
ARE.TO : 17.05 (-0.35%)
MSFT : 409.92 (+2.73%)
AMZN : 177.23 (+2.05%)
MRK : 131.22 (+0.38%)
3 Defensive Stocks for 'Sell in May' Season

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.

$SPX : 5,097.43 (+0.97%)
ABBV : 162.99 (-2.57%)
CBOE : 180.83 (-0.47%)
$VIX : 15.22 (-0.98%)
VZ : 39.62 (+1.02%)
Is AbbVie a Millionaire Maker?

Everything is going according to plan, and more growth is on the way.

ABBV : 162.99 (-2.57%)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

ABT : 107.31 (+0.42%)
KVUE : 19.00 (-0.11%)
SWAV : 329.02 (+0.01%)
ABBV : 162.99 (-2.57%)
BMY : 45.00 (+0.67%)
JNJ : 146.60 (-0.15%)
3 No-Brainer Dividend Stocks to Buy in April

Income investors will find a lot to like about these stocks.

ABBV : 162.99 (-2.57%)
GILD : 65.72 (+0.69%)
PFE : 25.39 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 172.92
2nd Resistance Point 171.10
1st Resistance Point 169.20
Last Price 162.99
1st Support Level 165.48
2nd Support Level 163.66
3rd Support Level 161.76

See More

52-Week High 182.89
Fibonacci 61.8% 163.05
Last Price 162.99
Fibonacci 50% 156.93
Fibonacci 38.2% 150.80
52-Week Low 130.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar